{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.0","upperLimit":"18.9","value":"16.3"},{"groupId":"OG001","lowerLimit":"10.1","upperLimit":"17.3","value":"11.7"},{"groupId":"OG002","lowerLimit":"8.1","upperLimit":"16.4","value":"14.6"},{"groupId":"OG003","lowerLimit":"8.5","upperLimit":"19.0","value":"10.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"228"},{"groupId":"OG001","value":"221"},{"groupId":"OG002","value":"44"},{"groupId":"OG003","value":"46"}],"units":"Participants"}],"description":"Measured in months from randomization to last contact or the earlier of the date of progression or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Paclitaxel 175 mg/m2 IV over 3 hours Day 1. Carboplatin (AUC=6) IV Day 1 Repeat q 3 weeks x 6-10 cycles","id":"OG000","title":"Regimen I - Uterine Carcinsarcoma Subjects"},{"description":"Ifosfamide 1.6 g/m2 IV days 1, 2, 3 Mesna Paclitaxel 135 mg/m2 by 3-hour infusion on Day 1 Repeat q 3 weeks x 6-10 cycles. G-CSF Support: Filgrastim or Pegfilgrastim beginning Day 4-6","id":"OG001","title":"Regimen II - Uterine Carcinsarcoma Subjects"},{"description":"Paclitaxel 175 mg/m2 IV over 3 hours Day 1 Carboplatin (AUC=6) IV Day 1 Repeat q 3 weeks x 6-10 cycles","id":"OG002","title":"Regimen III - Non-uterine Carcinsarcoma Subjects"},{"description":"Ifosfamide 1.6 g/m2 IV days 1, 2, 3 Mesna Paclitaxel 135 mg/m2 by 3-hour infusion on Day 1 Repeat q 3 weeks x 6-10 cycles. G-CSF Support: Filgrastim or Pegfilgrastim beginning Day 4-6","id":"OG003","title":"Regimen IV - Non-uterine Carcinsarcoma Subjects"}],"paramType":"MEDIAN","populationDescription":"All eligible patients","reportingStatus":"POSTED","timeFrame":"Approximately 9 years and 7 months","title":"Duration of Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}